Onychomycosis. Baseline results of an observational study

JR Schein Novartis Pharmaceuticals Corp, East Hanover, NJ 07936, USA.

Search for other papers by JR Schein in
Current site
Google Scholar
PubMed
Close
,
D Gause Novartis Pharmaceuticals Corp, East Hanover, NJ 07936, USA.

Search for other papers by D Gause in
Current site
Google Scholar
PubMed
Close
,
DM Stier Novartis Pharmaceuticals Corp, East Hanover, NJ 07936, USA.

Search for other papers by DM Stier in
Current site
Google Scholar
PubMed
Close
,
DP Lubeck Novartis Pharmaceuticals Corp, East Hanover, NJ 07936, USA.

Search for other papers by DP Lubeck in
Current site
Google Scholar
PubMed
Close
,
MM Bates Novartis Pharmaceuticals Corp, East Hanover, NJ 07936, USA.

Search for other papers by MM Bates in
Current site
Google Scholar
PubMed
Close
, and
R Fisk Novartis Pharmaceuticals Corp, East Hanover, NJ 07936, USA.

Search for other papers by R Fisk in
Current site
Google Scholar
PubMed
Close

The investigators present an analysis of baseline quality-of-life and patient-management approaches from an observational study of 150 patients being treated by podiatric physicians and dermatologists for onychomycosis. The majority (73%) made the initial office visit specifically because of their onychomycosis. Both men and women indicated that they had substantial physical discomfort as well as concerns related to appearance. Women reported significantly more problems than did men as a result of their onychomycosis. Physicians reported that 54% of patients suffered from toenail discomfort, 36% had pain while walking, 40% reported that their condition limited wearing of shoes, and 67% were embarrassed by the condition. The results of this study suggest that the treatment approach of podiatric physicians is more likely to address the palliative concerns of patients with onychomycosis, while the approach of dermatologists is more likely to attempt a definitive cure.

Save